15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Arcosa Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $125.00 to $150.00, so the covering firms are broadly aligned. The average target of $138.33 sits 5% below the current $145.67. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -9% this year and 9% next, consensus EPS building from about $1.01 next quarter toward $5.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Arcosa Inc.
As of Sep, 3 of 3 firms rate ACA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACA EPS & revenue forecast
EPS · NEXT QUARTER
$1.01
Range $0.93 – $1.06 · 4 analysts · -12% YoY
Next period, 4 analysts expect Arcosa Inc to earn $1.01 a share (range $0.93 – $1.06), versus $1.15 a year earlier. Full-year consensus is $4.29, growing to $5.12 the year after.
REVENUE · NEXT QUARTER
$638.7M
Range $635.8M – $643.0M · 4 analysts · -9% YoY
Revenue is expected to reach $638.7M (range $635.8M – $643.0M), -9.0% year-over-year. Full-year consensus is $2.6B, rising to $2.8B next year.
Top analysts covering Arcosa Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACA.
#1
Brent Thielman
DA Davidson · Rank #10
Buy
$125.00-14.2% to target
Overall win rate
56%
+ Follow
#2
Ian Zaffino
Oppenheimer · Rank #289
Buy
$110.00-24.5% to target
Overall win rate
38%
+ Follow
#3
Adam Seiden
Barclays
Buy
$140.00-3.9% to target
Coverage
—
+ Follow
#4
Brent Thielman
Oppenheimer
Buy
$150.00+3.0% to target
Coverage
—
+ Follow
ACA stock forecast FAQ
What is ACA's average 12-month price target?+
The 3 analysts with a live target average $138.33 for Arcosa Inc over the next 12 months, ranging from a $150.00 high to a $125.00 low.
Is ACA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ACA?+
The Street-high target is $150.00 (Oppenheimer), and the Street-low is $125.00 (DA Davidson). The average of all 3 active targets is $138.33.
How many Wall Street analysts cover ACA?+
3 analysts have an active rating on Arcosa Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACA?+
Among analysts who currently cover ACA, Brent Thielman of DA Davidson has the strongest overall Quantellect track record (Rank #10). Their current call is Buy with a $125.00 target.
What is Arcosa Inc's projected EPS for next quarter?+
The consensus estimate is $1.01 per share (range $0.93 – $1.06) across 4 analysts. Full-year EPS is projected at $4.29, rising to $5.12 the following year.
How much revenue is Arcosa Inc expected to report next quarter?+
Consensus revenue is $638.7M (range $635.8M – $643.0M). Full-year revenue is projected at $2.6B, growing to $2.8B next year.
Have analysts been upgrading or downgrading ACA lately?+
As of Sep, 3 of 3 firms rate ACA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
